DRL posts Q2 FY17 and H1FY17 results Usha Sharma Oct 25, 2016 In Q2 FY17, EBITDA is at Rs 6.4 billion and profit after tax at Rs 2.9 billion
Dr Reddy’s to acquire Teva’s product portfolio for US Market Usha Sharma Jun 13, 2016 The portfolio being acquired is a mix of filed ANDAs pending approval and an approved ANDA. It also comprises complex generic…
DRL posts consolidated revenues of Rs 37.6 billion, showing seven per cent growth YoY Usha Sharma Jul 31, 2015 Gross profit margin were at 61.1 per cent
